Search research articles
Contact Us
Filters
Showing results (111-120 of 153) with videos related to
Page
of 16
Sort By:
The Journal of Clinical Investigation
|
May 19, 2026
Genome-wide variation in cell-free DNA end motif entropy predicts immunotherapy response in head and neck cancer
Ravi Bandaru, Hailu Fu, Haizi Zheng, et al.
Oral Oncology
|
June 10, 2018
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L Ferris, George Blumenschein, Jerome Fayette, et al.
Journal for Immunotherapy of Cancer
|
July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.
Cancer
|
March 27, 2019
Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials
Carole Fakhry, Qiang Zhang, Maura L Gillison, et al.
Genome Research
|
December 14, 2021
Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers
David E Symer, Keiko Akagi, Heather M Geiger, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 13, 2026
Quality of life in patients with p16+ oropharyngeal cancer receiving accelerated radiotherapy with either cisplatin or cetuximab in the NRG/RTOG 1016 randomized controlled trial
Jolie Ringash, Pedro A Torres-Saavedra, Maura L Gillison, et al.
Cancer Research Communications
|
March 6, 2026
The KRAS-variant and cetuximab in HPV-positive oropharyngeal cancer - results from the NRG/RTOG 1016 trial
Joanne B Weidhaas, Jonathan Harris, Maura L Gillison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2025
Time Dependency for Human Papillomavirus Circulating Tumor DNA Detection after Chemoradiation as a Prognostic Biomarker for Localized Anal Cancer
Van K Morris, Weihong Xiao, Kangyu Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2020
Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8<sup>+</sup> Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results
Renata Ferrarotto, Diana Bell, Maria L Rubin, et al.
The New England Journal of Medicine
|
October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L Ferris, George Blumenschein, Jerome Fayette, et al.
Page
of 16
Search research articles
Search
Showing results (111-120 of 153) with videos related to
Sort By:
Page
of 16
The Journal of Clinical Investigation
|
May 19, 2026
Genome-wide variation in cell-free DNA end motif entropy predicts immunotherapy response in head and neck cancer
Ravi Bandaru, Hailu Fu, Haizi Zheng, et al.
Oral Oncology
|
June 10, 2018
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L Ferris, George Blumenschein, Jerome Fayette, et al.
Journal for Immunotherapy of Cancer
|
July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.
Cancer
|
March 27, 2019
Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials
Carole Fakhry, Qiang Zhang, Maura L Gillison, et al.
Genome Research
|
December 14, 2021
Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers
David E Symer, Keiko Akagi, Heather M Geiger, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 13, 2026
Quality of life in patients with p16+ oropharyngeal cancer receiving accelerated radiotherapy with either cisplatin or cetuximab in the NRG/RTOG 1016 randomized controlled trial
Jolie Ringash, Pedro A Torres-Saavedra, Maura L Gillison, et al.
Cancer Research Communications
|
March 6, 2026
The KRAS-variant and cetuximab in HPV-positive oropharyngeal cancer - results from the NRG/RTOG 1016 trial
Joanne B Weidhaas, Jonathan Harris, Maura L Gillison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2025
Time Dependency for Human Papillomavirus Circulating Tumor DNA Detection after Chemoradiation as a Prognostic Biomarker for Localized Anal Cancer
Van K Morris, Weihong Xiao, Kangyu Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2020
Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8<sup>+</sup> Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results
Renata Ferrarotto, Diana Bell, Maria L Rubin, et al.
The New England Journal of Medicine
|
October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L Ferris, George Blumenschein, Jerome Fayette, et al.
Page
of 16